


ATTEST: A phase 1 study of intravenous ATTR-01, a novel oncolytic adenovirus targeting $\alpha\text{v}\beta 6$ integrin, expressing anti-PD-L1 antibody in epithelial tumors

¹Adel Samson, ²Emiliano Calvo, ³Tatiana Hernandez, ⁴Magdalena Meissner, ⁵Victor Moreno, ⁶Eileen Parkes, ⁷Pavlina Spiliopoulou, ⁸Pia Donaldson, ⁸Julia DeCesare, ⁸David Krige, ⁸Hardev Pandha


¹St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK; ²HM Centro Integral Oncológico Clara Campal, Madrid, Spain; ³HM Nou Delfos, Barcelona, Spain; ⁴Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK; ⁵Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; ⁶Churchill Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK; ⁷Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK; ⁸Accession Therapeutics Limited, Oxford, UK.

Introduction to TROCEPT Platform

Oncolytic viruses encoding transgenes represent a tractable single-agent approach to targeted delivery of immunomodulatory therapies to tumors and have emerged as a promising modality in cancer therapy (Figure 1).




TROCEPT, a next-generation genetically modified adenovirus type-5, is rationally designed to overcome the limitations of existing IV delivered viruses and to increase tumor exposure. TROCEPT is uniquely de-targeted to avoid uptake by healthy cells, including the liver, by removal of normal cell tropisms, and is re-targeted to specifically infect and replicate in tumor cells that express the cancer marker $\alpha\text{v}\beta 6$ integrin (Figure 2).




TROCEPT Pre-clinical Data

Administration of TROCEPT leads to tumor-specific transgene payload (luciferase) production which increases with time as TROCEPT replicates in the tumor, compared to unmodified Ad5 which leads to body-wide transgene payload production. This also confirms the removal of the native tropisms in TROCEPT and specificity for $\alpha\text{v}\beta 6$ integrin (Figure 3).



NSG mice engrafted with human tumors expressing $\alpha\text{v}\beta 6$ integrin. Mice treated with vehicle demonstrated rapid tumor growth with 100% mortality. Intravenous injection of TROCEPT (1×10^{11} vp) into mice with large established tumors led to tumor control (Figure 4).




Introduction to ATTR-01

ATTR-01 is a first-in-class transgene modified variant of TROCEPT that, following infection of permissive tumor cells, expresses an anti-PD-L1 antibody.

Expression of the anti-PD-L1 checkpoint inhibitor in metastases (i.e locally), rather than via systemic delivery by IV infusion, may lead to higher local (tumor) concentrations of the drug and avoid exhaustion of systemic T cells, thereby increasing efficacy and reducing off tumor toxicity (Figure 5).

ATTEST is the first study of ATTR-01 in selected epithelial tumors with high frequency ($\geq 75\%$) of $\alpha\text{v}\beta 6$ expression.



ATTEST Study Design

ATTEST is an open label, multi-centre, dose escalation study of ATTR-01 (NCT06977737).

Part 1 is a dose escalation, using a Keyboard design, up to a maximum dose of 1×10^{13} viral particles ($n \leq 48$ participants).

Up to two doses will be expanded in Part 2 to explore the optimal dose(s) ($n \leq 24$ participants).

Participants will be recruited having progressed after ≥ 1 line of standard of care therapy with six cancer types (non-small cell lung, urothelial, head and neck, pancreatic, endometrial, cholangiocarcinoma; Figure 6) that typically demonstrate a high frequency ($\geq 75\%$) and high level of $\alpha\text{v}\beta 6$ integrin expression.

Pharmacodynamic outcomes will be assessed using tumor tissues and blood.

Analysis of tumor tissues (biopsies at baseline, Day 15 and Day 36) will explore viral replication, transgene expression and immune/inflammatory responses.

Study objectives are described in Table 1.






Table 1: Study Objectives	
Co Primary	Characterise the safety and tolerability of ATTR-01
	Recommended dose of ATTR-01
Secondary	Preliminary anti-tumor activity of ATTR-01
	Immunogenicity and viral persistence

ATTEST Study Schema

The ATTEST study design is described in Figure 7.



Enrolment

Up to 72 patients across 6 indications will be enrolled in Sub-protocol A.

Enrolment into the first cohort is ongoing.

7 clinical sites are active with further investigator's sought:

- St James Hospital, UK (Prof Adel Samson)
- Velindre Cancer Centre, UK (Dr Magdalena Meissner)
- Churchill Hospital, UK (Dr Eileen Parkes)
- Beatson Cancer Centre, UK (Dr Pavlina Spiliopoulou)
- CIOCC, Spain (Dr Emiliano Calvo)
- HM Nou Delfos, Spain (Dr Tatiana Hernandez)
- FJD, Spain (Dr Bernard Doger; Dr Victor Moreno)

